현재가
Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. The company is headqua...|
e.g. Promoter holding
Loading chart...
애널리스트 컨센서스 기준 EPS 및 매출 전망.
해당 기업의 실적 전망 데이터가 없습니다.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TTRADESTATI... | TRAD | $147.69M | 126.12 | 1.27 | — | — | — | — |
| 2. | TTRADESTATI... | TRAD | $147.69M | 126.12 | 1.27 | — | — | — | — |
| 3. | AAperture A... | APUR | $148.37M | — | — | — | — | — | — |
| 4. | NSouthern C... | NCO | $146.85M | — | — | — | — | — | — |
| 5. | XXFLH Capit... | XFLH | $146.33M | — | — | — | — | — | — |
연결 기준 (백만 단위) / 별도 보기 가능
| Quarter (M) | Sep 21 | Dec 21 | Mar 22 | Jun 22 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - |
| 0 | 0 | 0.49 | 0.52 | |
EBIT | 0 | 0 | -0.49 | -0.52 |
OPM % | - | - | - | - |
Non-Operating Income | 0 | 0 | -0.01 | -0.02 |
PBT | 0 | 0 | -0.5 | -0.54 |
Income Tax | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - |
Net Income | 0 | 0 | -0.5 | -0.54 |
NPM % | - | - | - | - |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
Revenue | 0 | 0 | 0 |
COGS | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 |
Gross Profit % | - | - | - |
| 0 | 1.67 | 0.9 | |
EBIT | 0 | -1.67 | -0.9 |
OPM % | - | - | - |
Non-Operating Income | 0 | -0.03 | -0.05 |
PBT | 0 | -1.7 | -0.96 |
Income Tax | 0 | 0 | 0 |
Tax Rate % | - | - | - |
Net Income | 0 | -1.7 | -0.96 |
NPM % | - | - | - |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
| 0 | 0.02 | 0.04 | |
| 0 | 0 | 0 | |
| 0 | 0 | 0 | |
| 1.3 | 0.04 | 0.11 | |
| 0 | 0 | 0 | |
Total Assets | 0 | 0.06 | 0.15 |
| 0 | 0 | 0 | |
| -2.29 | -1.07 | -0.74 | |
| 0 | 0.8 | 0.2 | |
| 0.66 | 0 | 0.5 | |
| 0 | 0.33 | 0.19 | |
Total Liabilities | 0 | 0.06 | 0.15 |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
| -1.62 | -2.07 | -0.28 | |
| 0 | 0 | 0 | |
| 2.92 | 0.8 | 0.3 | |
Net CFNet Cash Flow | 1.29 | -1.27 | 0.02 |
FCFFree Cash Flow | -1.62 | -2.07 | -0.28 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
| - | - | 105.6% | |
| - | -0.56 | -0.27 | |
| 1.95 | 0.12 | 0.22 | |
| - | - | 0.00 | |
Cash Conversion | - | 1.22 | 0.29 |
Payout Ratio | - | - | - |
| - | - | - | |
| - | - | - | |
| - | - | - | |
| 1.00 | 1.00 | 5.00 | |
| - | - | - | |
| - | - | - | |
| - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Alpex Acquisition Corp - Class A의 주주 구성 (SEC 공시 기준)
Shares sold short · updated twice a month
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 30 Oct 2026 | 733 | -99.1% | 1.00 | |
| 15 Oct 2026 | 80,484 | +62290.7% | 2.10 | |
| 30 Sep 2026 | 129 | -79.1% | 1.00 | |
| 15 Sep 2026 | 616 | -28.3% | 1.00 | |
| 31 Aug 2026 | 859 | +813.8% | 1.00 | |
| 14 Aug 2026 | 94 | +118.6% | 1.00 | |
| 31 Jul 2026 | 43 | -99.9% | 1.00 | |
| 15 Jul 2026 | 32,063 | 1.00 |
FINRA consolidated short interest, reported twice a month for every US listing.
Alpex Acquisition Corp - Class A의 SEC 공시 및 실적 발표 컨퍼런스콜 녹취록
What recent news says about Alpex Acquisition Corp - Class A, scored for sentiment.